Kisplyx (lenvatinib), in combination with everolimus, received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor targeted therapy. The opinion was based on results from a phase II trial that showed...
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
